Business
HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS
-Reports Fourth Quarter Revenue of $102.0 million with GAAP Diluted Earnings per Share of $0.46 and Non-GAAP Diluted Earnings per Share of $0.42 - -Reports
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"-Reports Fourth Quarter Revenue of $102.0 million with GAAP Diluted Earnings per Share of $0.46 and Non-GAAP Diluted Earnings per Share of $0.42 -\n -Reports Full Year 2021 Revenue of $443.3 million with GAAP Diluted Earnings per Share of $2.74 and Non-GAAP Diluted Earnings per Share of $2.00 -\n - 2022 Revenue Guidance of $530 to $560 Million Representing 20-26% Growth over Reported 2021 Revenue -\n -Recurring Revenue from Royalties in 2022 Expected to Grow by Approximately 50% over Record Royalties in 2021 to Approximately $300 Million -\n - 2022 GAAP Diluted EPS Guidance of $1.90 to $2.05 and 2022 Non-GAAP Diluted EPS Guidance of $2.05 to $2.20 -\n\n\nSAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on its recent corporate activities and outlook.\n\"Our performance in the fourth quarter closed out a year of strong performance across our business highlighted by record full year revenue from royalties, growing 130% from last year driven by the continued adoption of our wave 2 partner products subcutaneous DARZALEX® and Phesgo® (pertuzumab, trastuzumab, and hyaluronidase-zzxf),\" said Dr. Helen Torley, president and chief executive officer. \"In 2022, we look forward to building on 2021 momentum and anticipate 50% growth in our high-margin, recurring royalty revenues driven by further adoption of wave 2 products. We project further expansion and maturing of our pipeline, with 4 new targets entering Phase 1 development and at least 5 products advancing to Phase 2 or Phase 3 development. We are also excited to be starting development of a higher yield ENHANZE® API as well as a new rHuPH20 with extended room temperature stability and patent protection to 2032 in Europe and 2034 in the U.S.\"\n Fourth Quarter Partner Highlights: \nIn December 2021, Janssen received FDA approval for DARZALEX FASPRO® (daratumumab and hyaluronidase - fijh) in combination with Kyprolis® (carfilzomib) and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.In December 2021, ViiV initiated enrollment of a Phase 1 study arm to evaluate cabotegravir administered subcutaneously with ENHANZE®.In December 2021, Janssen initiated a Phase ...